Go Back to Match Results for ""
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Study Overview
This pilot clinical trial studies how rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder.
Study Description
The purpose of this study is to determine the feasibility of treating pediatric and young adult solid organ transplant recipients with newly diagnosed or recurrent Epstein-Barr virus (EBV)-positive CD20-positive post-transplant lymphoproliferative disease (PTLD) with a novel T cell therapeutic, allogeneic Latent Membrane Protein(LMP)1/LMP2-specific cytotoxic T-lymphocytes (third party latent membrane protein [LMP]-specific T cells), in a cooperative group setting.
Additional Information
- IRB Number: 1704975155 (PHO-FALLON-COG-ANHL1522)
- Research Study Identifier: TX7739
- Principal Investigator: Kamnesh Pradhan, MD
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required
